$665.47 Million in Sales Expected for Steris PLC (STE) This Quarter

Equities analysts expect Steris PLC (NYSE:STE) to post sales of $665.47 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Steris’ earnings. The lowest sales estimate is $661.50 million and the highest is $669.90 million. Steris posted sales of $646.77 million during the same quarter last year, which suggests a positive year over year growth rate of 2.9%. The firm is expected to report its next earnings results on Tuesday, February 6th.

According to Zacks, analysts expect that Steris will report full-year sales of $665.47 million for the current year, with estimates ranging from $2.60 billion to $2.62 billion. For the next fiscal year, analysts forecast that the firm will post sales of $2.72 billion per share, with estimates ranging from $2.71 billion to $2.74 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Steris.

Steris (NYSE:STE) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing the consensus estimate of $0.95 by ($0.01). The firm had revenue of $634.20 million for the quarter, compared to the consensus estimate of $629.02 million. Steris had a net margin of 5.59% and a return on equity of 11.49%. The business’s revenue was down 1.9% on a year-over-year basis. During the same period last year, the company posted $0.89 earnings per share.

STE has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Steris from a “hold” rating to a “buy” rating and set a $101.00 price objective for the company in a research note on Monday, October 9th. Raymond James Financial upped their price objective on shares of Steris from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, October 16th. KeyCorp reaffirmed a “buy” rating and set a $91.00 price objective on shares of Steris in a research note on Tuesday, October 17th. Finally, TD Securities upped their price objective on shares of Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $79.50.

Shares of Steris (NYSE STE) traded down $0.55 during trading hours on Friday, hitting $86.59. 400,600 shares of the stock traded hands, compared to its average volume of 425,667. The company has a market capitalization of $7,411.46, a P/E ratio of 51.54 and a beta of 1.27. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. Steris has a 52-week low of $65.26 and a 52-week high of $93.39.

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd were paid a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a yield of 1.43%. The ex-dividend date was Tuesday, November 21st. Steris’s payout ratio is currently 73.81%.

In related news, VP John Adam Zangerle sold 3,650 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total value of $321,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael J. Tokich sold 11,000 shares of the stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $92.00, for a total transaction of $1,012,000.00. Following the completion of the transaction, the insider now directly owns 58,588 shares of the company’s stock, valued at $5,390,096. The disclosure for this sale can be found here. 2.55% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. raised its stake in Steris by 1.4% in the second quarter. Advisor Group Inc. now owns 6,577 shares of the medical equipment provider’s stock worth $506,000 after buying an additional 91 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in Steris by 1.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 19,439 shares of the medical equipment provider’s stock worth $1,585,000 after purchasing an additional 254 shares during the period. Bahl & Gaynor Inc. grew its holdings in Steris by 0.9% in the second quarter. Bahl & Gaynor Inc. now owns 29,722 shares of the medical equipment provider’s stock worth $2,003,000 after purchasing an additional 275 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Steris by 10.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,276 shares of the medical equipment provider’s stock worth $267,000 after purchasing an additional 311 shares during the period. Finally, Ameritas Investment Partners Inc. grew its holdings in Steris by 1.5% in the second quarter. Ameritas Investment Partners Inc. now owns 25,416 shares of the medical equipment provider’s stock worth $2,071,000 after purchasing an additional 379 shares during the period. 89.40% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/05/665-47-million-in-sales-expected-for-steris-plc-ste-this-quarter.html.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply